Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. May 7, 2009; 15(17): 2151-2155
Published online May 7, 2009. doi: 10.3748/wjg.15.2151
Table 1 Patient characteristics and Jadad score of included trials
TrialsNumber of patients (BB + I/EBL)Mean age (yr) (BB + I/EBL)Males (BB + I/EBL)Follow-up duration (BB + I/EBL)Child-Pugh (A:B:C) (BB + I/EBL)EBL mean sessionsBB + ISMN (mg/d)Jadad score
Romero 200657/5251 ± 10/53 ± 1037:20/35:1712/11.5 mo23:25:9/ 17:30:53.4 ± 1.2 Nadolol 88 ± 68 5-ISMN 57.7 ± 276
PATCH 200251/5150.7 ± 13.2/52.4 ± 13.435:16/35:16248/356 d8:19:24/ 5:18:282Pronolol 80 (40-240) 5-ISMN5
LO 200261/6051 ± 13/52 ± 1247:14/46:1424/25 mo13:35:13/13:35:123.3 ± 1.1 Nadolol 48 ± 10 5-ISMN 30 ± 65
Villanueva 200172/7260 ± 12/58 ± 1443:29/47:2520/22 mo19:39:14/11:43:182.1 Nadolol 96 ± 56 5-ISMN 66 ± 226